Q-omics provides the consensus-scored LY6G6D profile across patient tissues and cancer cell-line models. LY6G6D expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, LY6G6D is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, LY6G6D RNA expression shows 9,747 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where LY6G6D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6G6D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6G6D survival associations across molecular data types. LY6G6D RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6G6D RNA expression–survival associations across cancer types. High LY6G6D expression shows unfavorable associations in LUAD, LGG, ACC, BLCA and KIRC, but favorable associations in SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for LY6G6D RNA expression.
This table summarizes LY6G6D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LY6G6D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6G6D shows lower tumor expression in BLCA, BRCA, PRAD and THCA and higher tumor expression in COAD and THCA. The COAD box plot shows higher LY6G6D RNA expression in tumor versus normal tissue (log2 FC = +3.523, t-test p < 0.001).
This table shows molecular features associated with LY6G6D in patient tissues and cancer cell lines. In patient samples, LY6G6D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LY6G6D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
